262
Participants
Start Date
February 4, 2022
Primary Completion Date
October 10, 2024
Study Completion Date
October 10, 2024
Oxbryta® (voxelotor) 500mg Tablets
Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
Montefiore Medical Center, The Bronx
UPMC Montefiore Hospital, Pittsburgh
UPMC Sickle Cell Center, Pittsburgh
UPMC Presbyterian, Pittsburgh
University of Pittsburgh Medical Center (UPMC), Pittsburgh
Nemours Alfred I duPont Hospital for Children, Wilmington
Nemours Children's Health, Wilmington, Wilmington
University of Maryland Medical Center, College Park
Inova Schar Cancer Institute, Fairfax
Duke University Hospital, Durham
Duke University Medical Center, Durham
ECU Health Medical Center Laboratory, Greenville
ECU Health Medical Center, Greenville
Levine Cancer Institute, Charlotte
Medical University of South Carolina Shawn Jenkins Women's and Children's Hospital, Charleston
Medical University of South Carolina, Charleston
Augusta University - Clinical Trials Office (clinic), Augusta
Augusta University, Augusta
Nemours Children's Specialty Care, Jacksonville
Foundation for Sickle Cell Disease Research, Hollywood
University of Miami Hospital, Miami
University of South Alabama, Mobile
St. Jude Children's Research Hospital, Memphis
Mississippi Center for Advanced Medicine, Madison
University of Illinois at Chicago (UIC) Clinical Research Center, Chicago
University of Illinois at Chicago (UIC) Sickle Cell Center, Chicago
University of Illinois Hospital and Health Sciences System(UI Health), Chicago
University of Illinois Hospital and Health Sciences System, Chicago
University of Texas Health Science Center at Houston, Houston
Children's Blood and Cancer Center at Dell Children's Medical Center, Austin
Dell Children's Medical Center, Austin
Phoenix Children's Hospital, Phoenix
Center for Inherited Blood Disorders, Orange
Bass Center for Childhood Cancer and Blood Disorders (Stanford Lucile Packard Children's Hospital), Palo Alto
Department of Pediatrics, Hematology section, Palo Alto
Stanford Children's Hospital, Palo Alto
University of California, San Diego, La Jolla
University of Connecticut Health, Farmington
University of Connecticut Health, Farmington
Boston University Medical Center, Boston
Newark Beth Israel Medical Center, Newark
East Carolina University, Greenville
INOVA Health, Falls Church
Lead Sponsor
Pfizer
INDUSTRY